![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » VIACELL FINALIZES IDE AND ANNOUNCES PLANS TO COMMENCE CLINICAL TRIAL OF VIACYTE IN OOCYTE CRYOPRESERVATION
VIACELL FINALIZES IDE AND ANNOUNCES PLANS TO COMMENCE CLINICAL TRIAL OF VIACYTE IN OOCYTE CRYOPRESERVATION
June 27, 2006
ViaCell, Incannounced today the United States Food and Drug Administration (FDA) has conditionally approved its Investigational Device Exemption (IDE) to evaluate its ViaCyte(SM) investigational product offering for the cryopreservation and thawing of human
oocytes for use during assisted reproductive technology.
ViaCell
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct